EC-Logo-2018_TM_CMYK.jpg
electroCore Expands Intellectual Property Portfolio
February 06, 2024 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., Feb. 06, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and...
EC-Logo-2018_TM_CMYK.jpg
electroCore Expands Intellectual Property Portfolio for Nerve Stimulation Technology
December 12, 2023 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., Dec. 12, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and...
EC-Logo-2018_TM_CMYK.jpg
Dr. Peter Staats to Host Analyst Day on the Science Behind gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) on Tuesday, November 21, 2023
November 15, 2023 08:15 ET | electroCore, Inc.
ROCKAWAY, N.J., Nov. 15, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that the Company’s Chief Medical...
EC-Logo-2018_TM_CMYK.jpg
electroCore Announces Third Quarter 2023 Financial Results
November 08, 2023 16:01 ET | electroCore, Inc.
Record third quarter 2023 net sales of $4.5 million, an increase of approximately 128% over third quarter 2022 Company increases revenue guidance for full year 2023 to $15.0 million - $15.5...
AEON Biopharma
AEON Biopharma Announces Topline Results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Episodic Migraine
October 19, 2023 16:05 ET | AEON Biopharma
– ABP-450 doses of 150 units and 195 units showed treatment effect of 4.8 days and 5.0 days, respectively, in the mean change from baseline in monthly migraine days (MMD) at weeks 21-24 but did not...
EC-Logo-2018_TM_CMYK.jpg
electroCore Announces Two-Year Extension of gammaCore™ Device Listing in the NHS Supply Chain Catalogue
October 17, 2023 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., Oct. 17, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial stage bioelectronic medicine and wellness company, announced today that gammaCore therapy will...
EC-Logo-2018_TM_CMYK.jpg
electroCore Expands Intellectual Property Portfolio for Non-Invasive Vagus Nerve Stimulation (nVNS) Technology
October 11, 2023 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and...
EC-Logo-2018_TM_CMYK.jpg
electroCore to Announce Third Quarter Financial Results on Wednesday, November 8
October 09, 2023 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., Oct. 09, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial...
EC-Logo-2018_TM_CMYK.jpg
electroCore to Participate in the Lytham Partners Fall 2023 Virtual Investor Conference
October 05, 2023 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., Oct. 05, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger,...
EC-Logo-2018_TM_CMYK.jpg
gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Improves Attention and Working Memory in Patients with Post Traumatic Stress Disorder (PTSD)
September 27, 2023 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., Sept. 27, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the publication of two peer...